True Wealth Design’s Cartesian Therapeutics RNAC Stock Holding History

True Wealth Design’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27K	Buy	122 +94	+336%	+$696	﹤0.01%	1890
2026 Q1	$173	Buy	+28	New	+$199	﹤0.01%	2355
2025 Q2	–	Sell	-2	Closed	-$27	–	2796
2025 Q1	$27	Buy	+2	New	+$36	﹤0.01%	2531

Other funds holding RNAC

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

True Wealth Design's RNAC Position: Q2 2026 in Review

True Wealth Design increased its Cartesian Therapeutics (RNAC) stake by 336% in Q2 2026, buying an estimated $696 and bringing the position to 122 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

True Wealth Design first reported a position in RNAC in Q1 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

True Wealth Design held 122 shares of Cartesian Therapeutics worth $1.27K as of Q2 2026.
True Wealth Design bought 94 Cartesian Therapeutics shares in Q2 2026, an estimated $696.
Cartesian Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1890 holding.
True Wealth Design first reported a position in Cartesian Therapeutics in Q1 2025 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.